iloprost
information and resources from the National Cancer Institute
NCI Thesaurus | iloprost
A prostacyclin analogue with potential chemopreventive activity. Iloprost binds to the prostacyclin receptor in various target cells, thereby causing vasodilation, inhibition of platelet aggregation, and decreased tumor cell adhesion to endothelium among other effects. Prostacyclin is a naturally occurring eicosanoid with anti-inflammatory, antineoplastic, and anti-metastatic properties. NCI Thesaurus | iloprost
A prostacyclin analogue with potential chemopreventive activity. Iloprost binds to the prostacyclin receptor in various target cells, thereby causing vasodilation, inhibition of platelet aggregation, and decreased tumor cell adhesion to endothelium among other effects. Prostacyclin is a naturally occurring eicosanoid with anti-inflammatory, antineoplastic, and anti-metastatic properties.
|
|
|
|
news articles
CoTherix launches trial of Ventavis in combination with sildenafil ... Mar 30, 2006
Therapeutics Daily (subscription) (press release), CoTherix, Inc., (CTRX) announced the initiation of a phase III trial of Ventavis (iloprost) Inhalation Solution in combination with sildenafil citrate. ...
Chest Service, Erasme University Hospital, Brussels, Belgium; and ... Mar 7, 2006
AJRCCM (subscription), Wittwer and colleagues evaluated the effect of donor pretreatment with inhaled iloprost before harvest and protracted cold ischemic storage in a pig model (9 ...
PAH: market ripe for expansion as big pharma interest increases Mar 27, 2006
Pharmaceutical Business Review ...by the launch of three new therapies and formulations in the US - United Therapeutics' IV Remodulin (treprostinil), CoTherix' Ventavis (iloprost), and Pfizer's ...
Encysive Shares Tumble On FDA Thelin Approvable Letter Mar 27, 2006
BioWorld Online (subscription), ...for the condition include the prostacyclins Remodulin (treprostinil sodium, from United Therapeutics Corp.) and the inhaled Ventavis (iloprost, from CoTherix ...
CoTherix to Webcast Presentations From Two Upcoming Investor ... Mar 23, 2006
Yahoo! News (press release) CoTherix's Ventavis® (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in ...
CoTherix Initiates Trial of Ventavis in Combination With ... Mar 8, 2006
PR Newswire (press release), ...(Nasdaq: CTRX) today announced the initiation of a Phase III trial of Ventavis(R) (iloprost) Inhalation Solution in combination with sildenafil citrate. ...
CoTherix and Respironics Announce Launch of New Portable ... Dec 13, 2005
PR Newswire (press release), ...(NASDAQ: RESP) announced today the launch of a new portable, battery-operated inhalation device for the delivery of Ventavis(R) (iloprost) Inhalation Solution. ...
Vanderbilt-Ingram Cancer Center testing new lung cancer treatment Nov 18, 2005
Nashville Business Journal, The study will look at the effects of the investigational drug Iloprost, which is used to treat pulmonary hypertension and peripheral vascular disease, which ...
Zacks Industry Outlook Highlights: Bio-Rad Labs, Gilead Sciences ... Dec 1, 2005
Business Wire (press release), ...consensus. The company's Ventavis(R) (iloprost) Inhalation Solution watched net product sales more than double to $8.4 million. ...
|
|
